Electronic Equipment, Instruments and Components
Company Overview of BiOptix Inc.
BiOptix Inc., an analytical instrumentation company, develops an array-based bio molecule detection systems and molecular interaction analysis instruments. The company’s products pipeline includes cell array biodetector systems, and biochip and optical cartridges; and pre-production small footprint and single cell biodetector systems. Its products are used to detect various molecules and micro organisms, including micro RNA, nucleic acids, proteins and antibodies, bacteria, viruses, carbohydrates, lipids, and low molecular weight drugs. The company serves clinical biomarkers and diagnostics, personalized medicine, infectious disease, drug discovery, biopharma and low molecular drug developme...
1775 38th Street
Boulder, CO 80301
Founded in 2003
Key Executives for BiOptix Inc.
Chief Executive Officer, President, and Member of Board of Directors
Co-Founder and Director of Research and Development
Vice President of Chemistry & Biochemistry
Compensation as of Fiscal Year 2014.
BiOptix Inc. Key Developments
BiOptix Appoints Scott Klakamp as Vice President of Chemistry and Biochemistry
Jan 22 15
BiOptix announced the appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry. Scott joins the company after previous scientific leadership positions at Takeda Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of his nearly 20 year career in therapeutics discovery and development.
BiOptix Appoints Ken Dickerson as Vice President of Sales
Jan 15 15
BiOptix announced the appointment of Ken Dickerson as Vice President of Sales. Ken joins the company from ACEA Biosciences where he was National Sales Director. Ken has also held sales management positions at Roche and GE Healthcare over his 20 year career.
BiOptix Announces Low Cost Surface Plasmon Resonance Services for Colorado-Based Researchers
Jul 8 13
BiOptix formally announced a unique to the industry research collaboration with the Biophysics Shared Resource Core Facility at the University of Colorado Denver, Anschutz Medical Campus. The collaboration, which is supported by BiOptix, is offering low cost SPR services for Colorado-based researchers on the new BiOptix 404pi, a next-generation surface plasmon resonance platform designed and built in Colorado. The BiOptix 404pi provides label-free analysis of protein-protein kinetics as well as protein-small molecule interactions. The Biophysics Shared Resource Facility is a user facility owned and operated by the Program in Structural Biology and Biochemistry at the University of Colorado, Denver. Since opening in 2001, the group has developed resources to study biomolecular structure and thermodynamics through surface plasmon resonance, CD/ORD, ITC, DSC, fluorescence spectroscopy, and analytical ultracentrifugation (AUC). In addition, the group also offers mass spectroscopy, LC/MS/MS, HPLC and amino acid analysis services. Surface Plasmon Resonance is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 13, 2015
July 30, 2014